1-20 of 106
Michel Delforge
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Clinical Trials & Observations
Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesús Berdeja, Sergio Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa McKiver, Paula Rodríguez-Otero
Journal: Blood
Blood (2024) 144 (23): 2389–2401.
https://doi.org/10.1182/blood.2024024582
Published: 2024
Includes: Supplemental data
Journal Articles

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Elena Zamagni, Tobias Silzle, Ivan Špička, Sabrin Tahri, Sarah Lonergan, Inger S. Nijhof, Antonietta Pia Falcone, Evangelos Terpos, Jakub Radocha, Roberto Mina, Guldane Cengiz Seval, Meral Beksac, Cesar Rodriguez, Marcelo C. Pasquini, Michel Delforge, Vania Hungria, Donna Reece, Philippe Moreau, Yael C. Cohen, Kihyun Kim, Dominik Dytfeld, Jiří Minařík, Irene Strassl, Jelena Bila, Martin Schreder, Janusz Krawczyk, Fredrik Schjesvold, Caroline Cicin-Sain, Christoph Driessen, Gordon Cook, Lugui Qiu, Gonzalo Martin Garate, Agoston Gyula Szabo, Roman Hájek, Marc S. Raab, Silvia Mangiacavalli, Hermann Einsele, Andrew Spencer, Mario Boccadoro, Helen Vassalou, Lixia Pei, Yingqi Shi, Maria Krevvata, Ryan Gruber, Caline Sakabedoyan, Margaret Cobb, Jagoda Jasielec, Himal Amin, Rachel Kobos, Pieter Sonneveld, Niels W.C.J. van de Donk
Journal: Blood
Blood (2024) 144 (Supplement 1): 494.
https://doi.org/10.1182/blood-2024-205608
Published: 2024
Journal Articles

Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study

Luca Bertamini, Cathelijne Fokkema, Paula Rodríguez-Otero, Mark van Duin, Niels W.C.J. Van De Donk, Mattia D'Agostino, Evangelos Terpos, Diego Vieyra, Ricardo M. Attar, Anna Sitthi-Amorn, Robin Carson, Michel Delforge, Christoph Driessen, Roman Hajek, Mario Boccadoro, Hermann Einsele, Annette Vangsted, Vincent H.J. Van Der Velden, Fredrik Schjesvold, Artur Jurczyszyn, Meral Beksac, Andrew Spencer, Annemiek Broijl, Tom Cupedo, Philippe Moreau, Pieter Sonneveld
Journal: Blood
Blood (2024) 144 (Supplement 1): 487.
https://doi.org/10.1182/blood-2024-199550
Published: 2024
Journal Articles

Comparative Effectiveness of Ciltacabtagene Autoleucel from the Cartitude-4 Trial Vs Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma - an Updated Overall Survival Analysis

Cyrille Touzeau, Brea Lipe, Abdullah Mohammad Khan, Binod Dhakal, Sandhya Nair, Jianming He, João Mendes, Seina Lee, Carolina Lonardi, Ana Slaughter, Nikoletta Lendvai, Jordan M. Schecter, Diana Chen, Man Zhao, Tzu-min Yeh, Xavier Leleu, Noemi Puig, Dominik Dytfeld, Elena Zamagni, Katja C. Weisel, Lionel Karlin, Michel Delforge, Paolo Corradini, Roberto Mina, Wilfried Roeloffzen, Surbhi Sidana
Journal: Blood
Blood (2024) 144 (Supplement 1): 7089.
https://doi.org/10.1182/blood-2024-205383
Published: 2024
Journal Articles

Efficacy of Carvykti in Cartitude-4 Versus Alternative Treatments from Daratumumab Clinical Trials for the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma

Michel Delforge, Irit Avivi Mazza, Maria- Victoria Mateos, Kristina Carlson, Keqin Qi, João Mendes, Seina Lee, Jordan M. Schecter, William Deraedt, Carolina Lonardi, Ana Slaughter, Diana Chen, Man Zhao, Kaitlyn Connors, Nitin Patel, Erika Florendo, Hermann Einsele, Binod Dhakal, Wilfried Roeloffzen
Journal: Blood
Blood (2024) 144 (Supplement 1): 7085.
https://doi.org/10.1182/blood-2024-201606
Published: 2024
Journal Articles

Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study

Michel Delforge, Joshua Richter, Yael C. Cohen, Paolo Corradini, Douglas W Sborov, Alexander M. Lesokhin, Jesus G Berdeja, Moshe E Gatt, Laura Paris, Laura Rosinol Dachs, Hang Quach, Manisha Kanwar, Olivier Catalani, Paresh Sewpaul, Elisabeth Wassner-Fritsch, Ameet Mishra, Kerstin Trunzer, Shaji Kumar
Journal: Blood
Blood (2024) 144 (Supplement 1): 4732.
https://doi.org/10.1182/blood-2024-199519
Published: 2024
Journal Articles

Remote Patient Monitoring for Early Detection of Cytokine Release Syndrome in Myeloma Patients: A Comparative Study between Standard Care and Remote Monitoring

Anneleen Vanhellemont, Annemarie Coolbrandt, Evi Vandeneede, Gwen Aerts, Lise Lynen, Yoline Soeffers, Annouschka Laenen, Peter Vandenberghe, Michel Delforge
Journal: Blood
Blood (2024) 144 (Supplement 1): 3664.
https://doi.org/10.1182/blood-2024-203013
Published: 2024
Journal Articles

Evaluation of the Safety and Efficacy of Denosumab in Patients with Multiple Myeloma and Severe Renal Impairment; Results from an IMWG Bone Subcommittee Study

Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Charalampia Kyriakou, Carlyn Rose Tan, Niels Abildgaard, Michel Delforge, Dorotea Beatriz Eugenia Fantl, Cristian M Seehaus, Emilie Carneiro, Cristina João, Saad Z. Usmani
Journal: Blood
Blood (2024) 144 (Supplement 1): 3343.
https://doi.org/10.1182/blood-2024-202539
Published: 2024
Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Pieter Sonneveld, Meletios A. Dimopoulos, Mario Boccadoro, Hang Quach, Phoebe Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosiñol Dachs, Michel Delforge, Wilfried Roeloffzen, Christoph Driessen, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Yanfang Liu, Jianping Wang, Emilie M.J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Eva G. Katz, Katharine S. Gries, Jiaqi Song, Kai Fai Ho, Paula Rodríguez-Otero, Joan Bladé, Philippe Moreau
Journal: Blood
Blood (2024) 144 (Supplement 1): 2000.
https://doi.org/10.1182/blood-2024-201630
Published: 2024
Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Pieter Sonneveld, Meletios A. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodríguez Otero, Joan Bladé, Philippe Moreau
Journal: Blood
Blood (2023) 142 (Supplement 2): LBA-1.
https://doi.org/10.1182/blood-2023-191911
Published: 2023
Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodriguez Otero
Journal: Blood
Blood (2023) 142 (Supplement 1): 96.
https://doi.org/10.1182/blood-2023-179152
Published: 2023
Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Paula Rodríguez Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Luciano Costa, Ravi Vij, Nizar J Bahlis, Philippe Moreau, Scott R. Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur S. Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesus G. Berdeja, Anna Truppel-Hartmann, Rashmi Bhatnagar, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-McKiver, Sergio A. Giralt
Journal: Blood
Blood (2023) 142 (Supplement 1): 1028.
https://doi.org/10.1182/blood-2023-178933
Published: 2023
Journal Articles

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Jens Hillengass, Adam D. Cohen, Mounzer E Agha, Michel Delforge, Tessa Kerre, Wilfried Roeloffzen, Hermann Einsele, Hartmut Goldschmidt, Katja Weisel, Marc S. Raab, Christof Scheid, Sebastien Anguille, Pieter Sonneveld, Sonja Zweegman, Jordan M. Schecter, Kevin C De Braganca, Carolyn Chang Jackson, Philip Vlummens, Helen Varsos, Christina Corsale, Deepu Madduri, Tzu-min Yeh, Pankaj Mistry, Tito Roccia, Qingxuan Song, Muhammad Akram, Octavio Costa Filho, Dong Geng, Yael C. Cohen, Niels W.C.J. Van De Donk
Journal: Blood
Blood (2023) 142 (Supplement 1): 1021.
https://doi.org/10.1182/blood-2023-178882
Published: 2023
Journal Articles

Outcomes of Patients with Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from the LocoMMotion + MoMMent Studies

Philippe Moreau, Maria-Victoria Mateos, Hartmut Goldschmidt, Esther Gonzalez Garcia, Britta Besemer, Marta Sonia Gonzalez Perez, Mohamad Mohty, Joanne Lindsey-Hill, Suriya Kirkpatrick, Michel Delforge, Emanuele Angelucci, Francesco Di Raimondo, Ravi Vij, Margaret Doyle, Kathleen Gray, Claire Albrecht, Vadim Strulev, Imène Haddad, Silva Saarinen, Lada Mitchell, Jozefien Buyze, Katja Weisel
Journal: Blood
Blood (2023) 142 (Supplement 1): 4698.
https://doi.org/10.1182/blood-2023-181235
Published: 2023
Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Triple-Class-Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Who Received at Least 3 Lines of Prior Antimyeloma Regimens in the KarMMa-3 Phase 3 Randomized Controlled Trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodríguez Otero
Journal: Blood
Blood (2023) 142 (Supplement 1): 1003.
https://doi.org/10.1182/blood-2023-173849
Published: 2023
Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3

Rachid Baz, Paula Rodriguez Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Ajay K. Nooka, Luciano Costa, Noopur S. Raje, Ingerid Weum Abrahamsen, Michel Delforge, Usama Gergis, Douglas W. Sborov, Sergio A. Giralt, Marc S. Raab, Tadao Ishida, Asya Varshavsky-Yanovsky, Taewoong Choi, Larry D. Anderson, Jr., Anna Truppel-Hartmann, Rashmi Bhatnagar, Fan Wu, Julia Piasecki, Jasper Felten, Andrea Caia, Mark Cook, Yi Lin
Journal: Blood
Blood (2023) 142 (Supplement 1): 4879.
https://doi.org/10.1182/blood-2023-174477
Published: 2023
Journal Articles

MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Elena Zamagni, Mario Boccadoro, Andrew Spencer, Michel Delforge, Donna E. Reece, Agoston Gyula Szabo, Hermann Einsele, Evangelos Terpos, Fredrik Schjesvold, Jelena Bila, Christoph Driessen, Meral Beksac, Gordon Cook, Cesar Rodriguez, Lixia Pei, Yingqi Shi, Caline Sakabedoyan, Jagaoda Jasielec, Himal Amin, Rachel Kobos, Pieter Sonneveld, Niels WCJ Van De Donk
Journal: Blood
Blood (2022) 140 (Supplement 1): 7289–7291.
https://doi.org/10.1182/blood-2022-159756
Published: 2022
Journal Articles

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Aurore Perrot, Thierry Facon, Torben Plesner, Saad Usmani, Shaji K Kumar, Nizar Jacques Bahlis, Cyrille Hulin, Robert Z. Orlowski, Hareth Nahi, Peter Mollee, Karthik Ramasamy, Murielle Roussel, Arnaud Jaccard, Michel Delforge, Lionel Karlin, Bertrand Arnulf, Ajai Chari, Huiling Pei, Niodita Gupta, Shuchita Kaila, Kathryn Matt, Katharine S. Gries, Robin Carson, Fredrik Borgsten, Katja Weisel
Journal: Blood
Blood (2022) 140 (Supplement 1): 1142–1145.
https://doi.org/10.1182/blood-2022-165524
Published: 2022
Journal Articles

Pomalidomide-Dexamethasone Effectiveness in t(11;14) Positive Relapsed Multiple Myeloma in Real-World Setting

Sudeep Karve, Shaji Kumar, Veronica Gonzalez De La Calle, Silvia Mangiacavalli, Chang-Ki Min, Efstathios Kastritis, Graca Esteves, Michel Delforge, Fernando Escalante, Jin Lu, Yang Liu, Max Bittrich, Charalampia Kyriakou, Andrew J. Yee, Emma Arriola, Jeremy A. Ross, Shivaji Manthena, Brian G.M. Durie
Journal: Blood
Blood (2021) 138 (Supplement 1): 3803.
https://doi.org/10.1182/blood-2021-149336
Published: 2021
Journal Articles

Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT

Nico Gagelmann, Dirk-Jan Eikema, Linda Koster, Tanja Netelenbos, Andrew McDonald, Anne-Marie Stoppa, Guido Kobbe, Achilles Anagnostopoulos, Gwendolyn Van Gorkom, Eric Deconinck, Claude-Eric Bulabois, Michel Delforge, Donald Bunjes, William Arcese, Péter Reményi, Maija Itälä-Remes, Lorenz Thurner, Zahit Bolaman, Yafour Nabil, Stephan Mielke, Hélène Labussière-Wallet, Patrick J Hayden, Meral Beksac, Stefan Schönland, Ibrahim Yakoub-Agha
Journal: Blood
Blood (2021) 138 (Supplement 1): 485.
https://doi.org/10.1182/blood-2021-152391
Published: 2021